Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.

Publication ,  Journal Article
Horwitz, SM; Ansell, S; Ai, WZ; Barnes, J; Barta, SK; Clemens, MW; Dogan, A; Goodman, AM; Goyal, G; Guitart, J; Halwani, A; Haverkos, BM ...
Published in: J Natl Compr Canc Netw
November 2, 2020

Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

November 2, 2020

Volume

18

Issue

11

Start / End Page

1460 / 1467

Location

United States

Related Subject Headings

  • Prognosis
  • Practice Guidelines as Topic
  • Oncology & Carcinogenesis
  • Lymphoma, T-Cell
  • Humans
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Horwitz, S. M., Ansell, S., Ai, W. Z., Barnes, J., Barta, S. K., Clemens, M. W., … Sundar, H. (2020). NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. J Natl Compr Canc Netw, 18(11), 1460–1467. https://doi.org/10.6004/jnccn.2020.0053
Horwitz, Steven M., Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, et al. “NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.J Natl Compr Canc Netw 18, no. 11 (November 2, 2020): 1460–67. https://doi.org/10.6004/jnccn.2020.0053.
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, et al. NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. J Natl Compr Canc Netw. 2020 Nov 2;18(11):1460–7.
Horwitz, Steven M., et al. “NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.J Natl Compr Canc Netw, vol. 18, no. 11, Nov. 2020, pp. 1460–67. Pubmed, doi:10.6004/jnccn.2020.0053.
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kim YH, Mehta-Shah N, Olsen EA, Pro B, Rajguru SA, Rozati S, Said J, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H. NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. J Natl Compr Canc Netw. 2020 Nov 2;18(11):1460–1467.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

November 2, 2020

Volume

18

Issue

11

Start / End Page

1460 / 1467

Location

United States

Related Subject Headings

  • Prognosis
  • Practice Guidelines as Topic
  • Oncology & Carcinogenesis
  • Lymphoma, T-Cell
  • Humans
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis